Nicholas D. Gollop

Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age

Michael Böhm, Javed Butler, Gerasimos Filippatos et al. · Journal of the American College of Cardiology · 2022 · 72 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD

Ruth Farmer, Ivan Beard, Syed Raza et al. · Clinical Therapeutics · 2021 · 56 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial

Stuart Pocock, João Pedro Ferreira, John Gregson et al. · European Heart Journal · 2021 · 53 citations · Full text

Medicine, Biostatistics, Cardiology +16

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of <scp>EMPEROR‐Reduced</scp>

Gerasimos Filippatos, Stefan D. Anker, Javed Butler et al. · European Journal of Heart Failure · 2022 · 50 citations · Full text

Pharmacy, Cardiology, Pharmacology +12

Long-lasting blood pressure lowering effects of nitrite are NO-independent and mediated by hydrogen peroxide, persulfides, and oxidation of protein kinase G1α redox signalling

Martin Feelisch, Takaaki Akaike, Kayleigh Griffiths et al. · Cardiovascular Research · 2019 · 46 citations · Full text

Life Sciences, Cell Biology, Physiology +16